AbsTrACT
Purpose To estimate the incidence, and describe the clinical features and short-term clinical outcomes of acute angle closure (AAC). Methods Patients with newly diagnosed AAC were identified prospectively over a 12-month period (November 2011 to October 2012) by active surveillance through the Scottish Ophthalmic Surveillance Unit reporting system. Data were collected at case identification and at 6 months follow-up. results There were 114 cases (108 patients) reported, giving an annual incidence of 2.2 cases (95% CI 1.8 to 2.6) or 2 patients (95% CI 1.7 to 2.4) per 1 00 000 in the whole population in Scotland. Precipitating factors were identified in 40% of cases. Almost one in five cases was associated with topical dilating drops. Best-corrected visual acuity (BCVA) at presentation ranged from 6/6 to perception of light. The mean presenting intraocular pressure (IOP) was 52 mm Hg (SD 11). Almost 30% cases had a delayed presentation of 3 or more days. At 6 months follow-up, 75% had BCVA of 6/12 or better and 30% were found to have glaucoma at follow-up. Delayed presentation (≥3 days) was associated with higher rate of glaucoma at follow-up (22.6% vs 60.8%, p<0.001), worse VA (0.34 vs 0.74 LogMAR, p<0.0001) and need for more topical medication (0.52 vs 1.2, p=0.003) to control IOP. Conclusion The incidence of AAC in Scotland is relatively low compared with the Far East countries, but in line with previous European data. Almost one in five cases were associated with pupil dilation for retinal examination.
InTroduCTIon
Glaucoma is the leading cause of irreversible blindness. 1 While primary angle-closure glaucoma (PACG) is thought to account for a quarter of all primary glaucoma cases compared with three quarters for primary open angle glaucoma (POAG), it is more visually destructive, with the proportions of blindness caused by each being almost equal. 1 Current estimates suggest 19%-42% cases of primary angle closure disease in European-derived population present acutely. 2 3 The epidemiology of acute angle closure (AAC) in Europeans is not well described. Current reported incidence rates are estimated from retrospective reviews of patient attendances and subsequent extrapolation of results [4] [5] [6] or from Hospital Episode Statistics data. 7 The reported incidence in European countries ranged from 1.4 to 4.2 per 100 000 per year. [4] [5] [6] The main aims of this study were to estimate the incidence of AAC in Scotland, investigate the ocular and demographic risk factors associated with AAC and the short-term clinical outcomes of AAC. This is the first prospective epidemiological study of AAC in Europe.
MeThods
Patients with newly diagnosed AAC were identified prospectively through active surveillance by the Scottish Ophthalmic Surveillance Unit (SOSU) during a 12-month period between 1 November 2012 and 31 October 2013. This methodology is commonly used by the sister organisation British Ophthalmic Surveillance Unit. 8 The surveillance scheme involves all permanently employed ophthalmologist (consultants and associate specialist) in Scotland. Before initiation of a study, the SOSU informs all ophthalmologist about the new ocular condition under investigation, including the specific case definition. At the end of each month, a report card is sent to each ophthalmologist, who then returns it specifying whether a new case had been seen that month. After case notification, reporting ophthalmologist was sent a baseline questionnaire by post to gather information on patient's demographic data, clinical findings and management. Another follow-up questionnaire was sent to reporting ophthalmologist again by post at 6 months. Only residents within Scotland with a new diagnosis of AAC were included in the study.
The inclusion criteria are: any two of the symptoms: blurring of vision; ocular or periocular pain; nausea or vomiting and antecedent history of intermittent blurring of vision with haloes; any of the signs: corneal oedema; unreactive mid-dilated pupil; iris bombe; conjunctiva injection and intraocular pressure (IOP) ≥30. 9 The examining ophthalmologist also needed to perform gonioscopy examination to confirm the presence of occluded angle in the affected eye. The presence of occludable angle in the fellow eye was acceptable if the clarity of the affected eye was not satisfactory. 'Occludable angle' was defined as an angle in which ≥180° (≥2 quadrants) of the posterior trabecular meshwork could not be seen. Exclusion criteria included neovascularisation and pseudophakia. The 2011 Scottish census was used to calculate the annual incidence per 1 00 000 of the population and those aged ≥30 years.
The definition of glaucoma was based on the International Society for Geographical and Epidemiological Ophthalmology classification, 10 namely:
Clinical science ► 'Glaucoma: 'glaucoma' is reserved for people with established, visually significant end-organ damage. It is defined as structural optic disc damage exceeding the specified limit (glaucomatous optic neuropathy) and glaucomatous visual field loss. .5th percentile or (B) the visual acuity <3/60 and the eye shows evidence of glaucoma filtering surgery. Visual acuity was recorded at presentation and at 6-month follow-up. In line with previous studies, a VA of <6/60 Snellen in the affected eye was classified as severe visual impairment. 11 12 Reporting ophthalmologists were also asked if cases were eligible for registration as partial sighted (sight impaired) or blind (severely sight impaired) according to the criteria defined by the Department of Health on Certificate of Vision Impairment. 13 The clinical outcomes were compared between those who had delayed presentation of 3 days or more and those who presented <3 days. Chi-square test was used to compare number of coexisting glaucoma and the need for surgical intervention between the two groups. An independent t-test was applied to compare the mean best-corrected visual acuity (BCVA), mean number of topical medications and mean durations of hospital admissions between the two groups. A p value of <0.05 was considered to be statistically significant. Analysis was performed using Statistical Package for Social Sciences software V.20.0 (SPSS, Chicago, Illinois, USA). Caldicott approval and ethics permission were granted.
resulT Incidence
There were 118 AAC cases reported during the 12-month period between 1 November 2012 and 31 October 2013 and the SOSU card return rates for the study was 68%. The reporting ophthalmologists did not return the subsequent questionnaires for 19 cases, 4 cases were excluded as having secondary mechanisms (aqueous misdirection, n=2; pseudophakic pupil block, n=1; neovascular glaucoma, n=1). Incidence rates were calculated on the basis of 114 (108 patients) reported cases. Clinical outcomes were reported using data from 95 cases with available data. In 2011 census, Scotland had a population of 5295403 and 65% (n=3 460 281) were aged 30 years and older.
14 With 114 primary AAC cases (included 19 cases for whom the follow-up questionnaire was not returned) or 108 patients over 12 months, the estimated annual incidence of AAC in Scotland was 2.2 cases (95% CI 1.8 to 2.6) or 2 patients (95% CI 1.7 to 2.4) per 1 00 000 of the whole population and 3.3 cases (95% CI 2.8 to 3.9) or 3.1 patients (95% CI 2.6 to 3.7) per 1 00 000 for population aged ≥30 years. Table 1 summarises the baseline characteristics of the 95 eyes of 89 patients. Eighty-three patients presented with unilateral AAC attack and six patients presented with bilateral AAC. Mean patient age was 70.9 (SD 9.1, range 53-91 years). The ratio of males to females was 1:1.6. The incidence of AAC was higher during winter 2012 and autumn 2013, with 28 cases (29%) and 29 cases (31%), respectively. Precipitating factors were identified in 38 cases (40%) (table 1), the common precipitating factors were topical eye drops for pupil dilatation (n=18), beta-2 agonist (n=6) and selective serotonin receptor inhibitor (n=5). Fifty-three per cent of patients were symptomatic for 1-2 days before presenting to ophthalmologist. Fourteen patients (15%) were seen within 24 hours of their symptoms, and 27 (28%) had delayed presentations of 3 days or more. There were 33 patients (35%) with a visual acuity worse than 6/60 at presentation. The mean IOP was 52 mm Hg (range 30-78). All cases had IOP ≥30 and unreactive mid-dilated pupil. Table 2 shows the management of AAC in the first 72 hours and during the 6 months follow-up. Every patient had topical medications at presentation to lower pressure. Majority of patients had laser peripheral iridotomy (87%), intravenous acetazolamide (85%) and oral acetazolamide (85%). Intravenous mannitol was only used in 15% of patients. Rarely, patients needed surgical peripheral iridectomy (n=1), cyclodiode laser (n=1) and phacoemulsification and IOL implant (n=1) within the first 72 hours of management. Only 68% of patients had prophylactic laser peripheral iridotomy on the fellow eye.
Presenting features

Treatment
During the 6 months follow-up, 38% of patients were still on topical pressure lowering medications and 35% of patients had undergone phacoemulsification and IOL implant on the affected eye.
outcomes/ follow-up
The 6-month follow-up questionnaire return rate was 94% (89/95). Table 3 summarises the clinical characteristics. Seventy-five per cent of patients achieved vision of 6/12 or better in 6 months. Unfortunately, six patients (7%) had vision of 6/60 or worse. Of those patients, five had glaucoma at follow-up and one had retina vein occlusion. Mean IOP had also improved from the mean of 52 to 16 mm Hg. The average days of hospital admission and outpatient visits were 1.6 days and 3.7 visits, respectively. Thirty-three per cent of patients were found to have glaucoma during follow-up. None of the patients was eligible for sight impairment registration after AAC attacks.
As shown on table 4, patients with delayed presentation of 3 days or more had a significantly higher rate of glaucoma at follow-up (22.6% vs 60.8%, p<0.001), worse BCVA (0.34 vs 0.74 LogMAR, p<0.0001) and depended on more types topical medication (0.52 vs 1.2, p=0.003) to control IOP.
dIsCussIon
This is the first prospective epidemiological study of AAC in the Europe. Our study estimates an annual incidence of 2.2 cases or 2.0 patients per 1 00 000 in general population and 3.3 cases or 3.1 patients per 1 00 000 in population for those aged ≥30 years.
There is minimal contemporary data for comparison, with historical incidence rates of 4.2 per 1 00 000 population in Israel in 1985 4 ; 3.8 per 1 00 000 population in Finland for the period between 1973 and 1986. 6 Interestingly, our incidence rate is similar to that estimated in a recent analysis of AAC cases presenting to a single tertiary referral hospital with subsequent extrapolation to Scotland as a whole, whereby the expected annual incidence was 1.4 patients per 1 00 000 per year in Scotland. 
Clinical science
There have been recent reports that the incidence of AAC may be reducing with time. An analysis of Hospital Episode Statistics data from England reported in 2010 that the incidence of AAC appeared to have halved over the past decade presumably due to increasing number of laser peripheral iridotomies performed, phacoemulsification cataract surgery and greater awareness of angle-closure mechanisms as an important, treatable cause of glaucoma disease. 7 15 A similar analysis using data from the Information Service Division (ISD) Scotland reported the rate of AAC to have reduced by 46% over the period between 1998 and 2012. 15 In the far east, Singapore has much higher incidence of AAC, Seah et al reported 12.2 per 100 000 in populations aged over 30 years. This is most likely secondary to different ethnic groups. Scotland has 96% of white population and Singapore has 80% of Chinese origin. It is well established that Chinese has higher rate of PACG. 9 16 Precipitating factors were identified in 40% of cases. Almost one in five of overall cases were associated with recent topical dilating drops administered as part of a recent routine community optometric examination. Another one in five cases were associated with prescribed and/or over-the-counter medications, thus highlighting the importance of careful clinical history taking including detailed drug history when assessing patients with AAC. For prescribed medications, beta-2 agonist (n=6), antiselective serotonin receptor inhibitor (n=5) and tricyclic antidepressant (n=3) were the frequent causes in our cases. There were only two AACs precipitated by over-the-counter medications, namely nasal decongestant (n=1) and antihistamine (n=1). For comparison, the case series by Choong et al identified possible precipitating factors in only 19% of cases. 17 Almost one in five (19%) AACs were associated with topical dilating drops. The risk of AAC was reported to be low in some population-based studies. The Rotterdam study reported an incidence of 3 in 10 000 subjects after diagnostic mydriasis with tropicamide 0.5% and phenylephrine 5%, followed by thymoxamine 0.5% (miosis agent) after ophthalmological examination. 18 The Baltimore Eye Survey showed no episode of AAC after dilation of 4870 subjects. 19 Lagan et al identified three cases of angle closure associated with mydriasis for diabetic retinopathy screening over 4 years and estimate annual incidence of 0.75 case per year. 20 As the use of topical mydriatic drops is common cause of AAC in this study, we would like to highlight the importance of anterior chamber angle depth assessment (eg, by van Herrick test) prior to administering mydriatic drops and informing patients about the symptoms of AAC and given clear instructions of where and when to seek help in the event of AAC attack.
In our study, 28% of AAC cases were diagnosed 3 or more days after the onset of symptoms. Compared with those who presented <3 days, they were more likely to be found to have glaucoma at follow-up (p<0.001) and have worse BCVA (p<0.001). This is similar to the previous report on the outcomes AAC in Asian population. Tan et al found that longer duration of symptoms and time taken to break acute attack are associated with primary angle closure glaucoma. 21 There is limited evidence about the percentage of AAC eyes that develop PACG in the white Caucasian population. Our study shows that at 6 months follow-up, 33% have glaucoma and 38% were still on topical IOP-lowering medication. This result is consistent with previous publications on white Caucasians. 5 17 However, a more recent study by Andreatta et al suggested a lower rate of 15% on a long-term follow-up, this may be explained by the exclusion of PACG at presentation in their study. 22 At 6 months follow-up, our study showed that only six patients (7%) had corrected distant visual acuity of <6/60, compared with 35% at presentation. Glaucomatous optic neuropathy is responsible for five out of six patients (83%) in our study. Previous studies on Caucasians reported reduced BCVA of <6/60 in 12%-15% of eyes in short-term and longterm follow-up. 11 17 22 23 Interestingly, Tan et al showed that 90.5% of their cohort had BCVA >6/12 at final follow-up and none had BCVA of worse than 6/60. 21 The inconsistent results may be due the variability of follow-up durations, different racial origin and different inclusion criteria. Based on the criteria specified by Department of Health on Certificate of Vision Impairment, none of our patients were eligible for sight impairment registration following AAC attack.
This study used a proven method of active case ascertainment to identify incident cases 8 ; however, there are several limitations. First, there are likely to be source of under-ascertainment such as cases not being made aware to the consultant ophthalmologist, non-participation and unreported cases. Hence, the incidence reported in this study is a minimum rate. Second, we modified inclusion criteria for AAC used by other population study. 9 We only included patients with IOP >30 at presentation instead of 19 and subjects did not necessary have to have four out of five of the signs as suggested. 9 We believed that if we were to follow the inclusion criteria as Seah et al, true AAC cases would have been missed. All our patients, however, have unreactive mid-dilated pupils, IOP >30 and occluded angle on the affected eye or occludable angle on the fellow eye.
In conclusion, this is the first prospective incidence study of AAC in Scotland. We estimate the incidence to be 2.2 cases per 1 00 000 of the general population or 3.4 per 1 00 000 for those aged ≥30 years for 2011-2012, where 96% of the populations are white Caucasian. Almost one in five cases were associated with pupil dilatation for retinal examination.
